These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 24643178)

  • 1. Host responses to infection with human papillomavirus.
    Stanley MA; Sterling JC
    Curr Probl Dermatol; 2014; 45():58-74. PubMed ID: 24643178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunobiology of HPV and HPV vaccines.
    Stanley M
    Gynecol Oncol; 2008 May; 109(2 Suppl):S15-21. PubMed ID: 18474288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune responses to human papilloma viruses.
    Stanley MA
    Indian J Med Res; 2009 Sep; 130(3):266-76. PubMed ID: 19901436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epithelial cell responses to infection with human papillomavirus.
    Stanley MA
    Clin Microbiol Rev; 2012 Apr; 25(2):215-22. PubMed ID: 22491770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HPV modulation of host immune responses.
    Feller L; Wood NH; Khammissa RA; Chikte UM; Meyerov R; Lemmer J
    SADJ; 2010 Jul; 65(6):266-8. PubMed ID: 20879650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination.
    Stern PL
    J Clin Virol; 2005 Mar; 32 Suppl 1():S72-81. PubMed ID: 15753015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune responses to human papillomavirus.
    Stanley M
    Vaccine; 2006 Mar; 24 Suppl 1():S16-22. PubMed ID: 16219398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunobiology of human papillomavirus infection and vaccination - implications for second generation vaccines.
    Stanley M; Gissmann L; Nardelli-Haefliger D
    Vaccine; 2008 Aug; 26 Suppl 10():K62-7. PubMed ID: 18847558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune activation in cervical neoplasia: cross-sectional association between plasma soluble interleukin 2 receptor levels and disease.
    Hildesheim A; Schiffman MH; Tsukui T; Swanson CA; Lucci J; Scott DR; Glass AG; Rush BB; Lorincz AT; Corrigan A; Burk RD; Helgesen K; Houghten RA; Sherman ME; Kurman RJ; Berzofsky JA; Kramer TR
    Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):807-13. PubMed ID: 9332763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter.
    Welters MJ; de Jong A; van den Eeden SJ; van der Hulst JM; Kwappenberg KM; Hassane S; Franken KL; Drijfhout JW; Fleuren GJ; Kenter G; Melief CJ; Offringa R; van der Burg SH
    Cancer Res; 2003 Feb; 63(3):636-41. PubMed ID: 12566307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune evasion mechanisms of human papillomavirus: An update.
    Steinbach A; Riemer AB
    Int J Cancer; 2018 Jan; 142(2):224-229. PubMed ID: 28865151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HPV: from infection to cancer.
    Stanley MA; Pett MR; Coleman N
    Biochem Soc Trans; 2007 Dec; 35(Pt 6):1456-60. PubMed ID: 18031245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
    Pinto LA; Edwards J; Castle PE; Harro CD; Lowy DR; Schiller JT; Wallace D; Kopp W; Adelsberger JW; Baseler MW; Berzofsky JA; Hildesheim A
    J Infect Dis; 2003 Jul; 188(2):327-38. PubMed ID: 12854090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune responses against human papillomavirus (HPV) infection and evasion of host defense in cervical cancer.
    Sasagawa T; Takagi H; Makinoda S
    J Infect Chemother; 2012 Dec; 18(6):807-15. PubMed ID: 23117294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evasion of host immune defenses by human papillomavirus.
    Westrich JA; Warren CJ; Pyeon D
    Virus Res; 2017 Mar; 231():21-33. PubMed ID: 27890631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins.
    Davidson EJ; Boswell CM; Sehr P; Pawlita M; Tomlinson AE; McVey RJ; Dobson J; Roberts JS; Hickling J; Kitchener HC; Stern PL
    Cancer Res; 2003 Sep; 63(18):6032-41. PubMed ID: 14522932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The host response to lesions induced by human papillomavirus.
    Stanley M; Coleman N; Chambers M
    Ciba Found Symp; 1994; 187():21-32; discussion 32-44. PubMed ID: 7796671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HPV induced cervical carcinogenesis: molecular basis and vaccine development.
    Kaufmann AM; Backsch C; Schneider A; Dürst M
    Zentralbl Gynakol; 2002 Nov; 124(11):511-24. PubMed ID: 12796844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
    Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM
    Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of human papillomaviruses with the host immune system: a well evolved relationship.
    Frazer IH
    Virology; 2009 Feb; 384(2):410-4. PubMed ID: 18986661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.